August 12, 2018 – Findings from a retrospective case-control study were published online August 8, 2018, in JAMA Dermatology indicate that the use of certain dipeptidyl peptidase 4 (DPP-4) inhibitor drugs are associated with a small but significantly elevated risk for developing bullous …

Risk of Bullous Pemphigoid with Type 2 Diabetes Drugs Read more »

May 06, 2018 – In April 2016 the American Food and Drug Administration (FDA) took regulatory action by mandating label changes with new warnings about an increased risk of heart failure for  new diabetes medicines in the dipeptidyl peptidase-4 (DPP-4) …

Heart attacks and stroke: The risk of DPP-4 anti-diabetes drugs Read more »